Genetic Variants in the Vitamin D Receptor Are Associated with Advanced Prostate Cancer at Diagnosis: Findings from the Prostate Testing for Cancer and Treatment Study and a Systematic Review. Export

@article{citeulike:6083183, abstract = {Low levels of plasma vitamin D have been implicated as a possible risk factor for both prostate cancer incidence and advanced disease, and recent phase II trials suggest that vitamin D supplementation might delay progression of prostate cancer. Common polymorphisms in the vitamin D receptor (VDR) are associated with VDR activity and are therefore potentially useful proxies for assessing whether vitamin D is causally related to advanced prostate cancer. We genotyped five well-known VDR polymorphisms in 1,604 men with prostate cancer from the Prostate Testing for Cancer and Treatment study. Our aim was to examine the association between VDR polymorphisms and cancer stage (localized versus advanced) as well as cancer grade (Gleason score <7 versus >/=7). Moreover, we also carried out a systematic review and meta-analysis of 13 similar studies. As a result of our meta-analysis, we revealed three polymorphisms, BsmI, ApaI, and TaqI, associated with high Gleason score with an overall summary odds ratios (95\% confidence intervals) of 1.12 (1.00-1.25; bb versus BB + Bb), 1.25 (1.02-1.53; aa versus AA + Aa), and 0.82 (0.69-0.98; Tt + tt versus TT), respectively. The haplotype analysis revealed that the BsmI (B)-ApaI (A)-TaqI (t) participants compared with BsmI (b)-ApaI (a)-TaqI (T) individuals were less likely to have high Gleason scores (odds ratio, 0.84; 95\% confidence interval, 0.71-1.00; P(unadjusted) = 0.050; P(adjusted) = 0.014). Our finding provides some support for the hypothesis that low levels of vitamin D may increase the risk of prostate cancer progression. (Cancer Epidemiol Biomarkers Prev 2009;18(11):2874-81).}, author = {Chen, Lina and Davey Smith, George and Evans, David M. and Cox, Angela and Lawlor, Debbie A. and Donovan, Jenny and Yuan, Wei and Day, Ian N. and Martin, Richard M. and Lane, Athene and Rodriguez, Santi and Davis, Michael and Zuccolo, Luisa and Collin, Simon M. and Hamdy, Freddie and Neal, David and Lewis, Sarah J.}, citeulike-article-id = {6083183}, citeulike-linkout-0 = {http://dx.doi.org/10.1158/1055-9965.EPI-09-0544}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/19861519}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=19861519}, day = {27}, doi = {10.1158/1055-9965.EPI-09-0544}, issn = {1538-7755}, journal = {Cancer epidemiology, biomarkers \& prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology}, keywords = {cancer, d, genetic, polymorphism, prostate, vdr, vitamin}, month = {October}, posted-at = {2009-11-07 18:01:16}, priority = {2}, title = {Genetic Variants in the Vitamin D Receptor Are Associated with Advanced Prostate Cancer at Diagnosis: Findings from the Prostate Testing for Cancer and Treatment Study and a Systematic Review.}, url = {http://dx.doi.org/10.1158/1055-9965.EPI-09-0544}, year = {2009} }

TY - JOUR ID - citeulike:6083183 L3 - citeulike-article-id:6083183 N2 - Low levels of plasma vitamin D have been implicated as a possible risk factor for both prostate cancer incidence and advanced disease, and recent phase II trials suggest that vitamin D supplementation might delay progression of prostate cancer. Common polymorphisms in the vitamin D receptor (VDR) are associated with VDR activity and are therefore potentially useful proxies for assessing whether vitamin D is causally related to advanced prostate cancer. We genotyped five well-known VDR polymorphisms in 1,604 men with prostate cancer from the Prostate Testing for Cancer and Treatment study. Our aim was to examine the association between VDR polymorphisms and cancer stage (localized versus advanced) as well as cancer grade (Gleason score <7 versus >/=7). Moreover, we also carried out a systematic review and meta-analysis of 13 similar studies. As a result of our meta-analysis, we revealed three polymorphisms, BsmI, ApaI, and TaqI, associated with high Gleason score with an overall summary odds ratios (95% confidence intervals) of 1.12 (1.00-1.25; bb versus BB + Bb), 1.25 (1.02-1.53; aa versus AA + Aa), and 0.82 (0.69-0.98; Tt + tt versus TT), respectively. The haplotype analysis revealed that the BsmI (B)-ApaI (A)-TaqI (t) participants compared with BsmI (b)-ApaI (a)-TaqI (T) individuals were less likely to have high Gleason scores (odds ratio, 0.84; 95% confidence interval, 0.71-1.00; P(unadjusted) = 0.050; P(adjusted) = 0.014). Our finding provides some support for the hypothesis that low levels of vitamin D may increase the risk of prostate cancer progression. (Cancer Epidemiol Biomarkers Prev 2009;18(11):2874-81). JF - Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology SN - 1538-7755 TI - Genetic Variants in the Vitamin D Receptor Are Associated with Advanced Prostate Cancer at Diagnosis: Findings from the Prostate Testing for Cancer and Treatment Study and a Systematic Review. KW - cancer KW - d KW - genetic KW - polymorphism KW - prostate KW - vdr KW - vitamin AU - Chen, Lina AU - Davey Smith, George AU - Evans, David AU - Cox, Angela AU - Lawlor, Debbie AU - Donovan, Jenny AU - Yuan, Wei AU - Day, Ian AU - Martin, Richard AU - Lane, Athene AU - Rodriguez, Santi AU - Davis, Michael AU - Zuccolo, Luisa AU - Collin, Simon AU - Hamdy, Freddie AU - Neal, David AU - Lewis, Sarah PY - 2009/10/27/ UR - http://dx.doi.org/10.1158/1055-9965.EPI-09-0544 ER -